PYRIMIDINONES AS FACTOR XIA INHIBITORS

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising thes...

Full description

Saved in:
Bibliographic Details
Main Authors Zhu Yeheng, Pinto Donald J.P, Ewing William R, Yang Wu, De Lucca lndawati, Smith II Leon M, Corte James R, Fang Tianan, Orwat Michael J, Pabbisetty Kumar Balashanmuga, Dilger Andrew K, Wang Yufeng, Wexler Ruth R
Format Patent
LanguageEnglish
Published 22.12.2016
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Bibliography:Application Number: US201615221142